British company AstraZeneca has signed a $247 million agreement with the American company Absci to develop an anti-cancer agent using AI in the pharmaceutical industry. The collaboration aims to leverage AI technology to produce proteins for tumor treatment, aligning with AstraZeneca's primary focus on this field.

‍

This deal is part of the collective efforts of leading pharmaceutical companies and emerging AI companies to develop new disease treatments while reducing research and development costs. It enhances the synergy between technology and medicine and reflects the rapid progress in the use of artificial intelligence in the pharmaceutical industry.